Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Shares Outstanding (Diluted Average) (2019 - 2025)

Maxcyte (MXCT) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $106.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 1.51% to $106.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.4 million through Dec 2025, up 1.51% year-over-year, with the annual reading at $106.4 million for FY2025, 1.51% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $106.4 million at Maxcyte, roughly flat from $106.6 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $106.6 million in Q3 2025, with the low at $84.7 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $101.3 million, with a median of $103.3 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 37.47% in 2021, then grew 1.13% in 2024.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $90.6 million in 2021, then grew by 12.23% to $101.7 million in 2022, then grew by 1.54% to $103.3 million in 2023, then rose by 1.53% to $104.8 million in 2024, then increased by 1.51% to $106.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $106.4 million, $106.6 million, and $106.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.